Stockscreener 앱 받기
0.98
46.27%
0.31
Vaccinex Inc 주식(VCNX)의 최신 뉴스
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) versus Vaccinex (NASDAQ:VCNX) - Defense World
Micro Cap Biotech Secures $60M to Advance Alzheimer’s Treatment, Shares Surge - The Globe and Mail
Vaccinex secures $60 million funding for Alzheimer’s drug development By Investing.com - Investing.com Australia
Vaccinex announces $60M revenue sharing agreement with PDV - MSN
Vaccinex Secures $60 Mln To Advance Enlarged Phase 2b Alzheimer's Trial - Nasdaq
Vaccinex secures $60 million funding for Alzheimer’s drug development - Investing.com
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment - Quiver Quantitative
Net Asset Value(s) - The Manila Times
Biometric Identification / Cybersecurity SaaS Solutions Provider BIO-key Presents at DealFlow Discovery Investor Conference Jan. 28 & 29 in Atlantic City, NJ - The Manila Times
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease - The Manila Times
MBAK Energy Solutions, Inc. (OTC:MBAK) partners with Carbon Zero Mobility in Kenya and the University of Michigan on Charger Design - The Manila Times
Outpace Wins 144+ SEO Awards, Establishing Itself as one of the Best SEO Agencies in the US - The Manila Times
Renewal Fuels (RNWF) & Its Subsidiary American Fusion Highlight Near-Term Commercial Fusion Strategy, Underscoring Key Distinctions Between Deployable Energy Infrastructure & Experimental Fusion Programs - The Manila Times
SunPower Q3’25 10Q Report Filed - The Manila Times
OSS Receives Follow-On Production Order from Safran Federal Systems - The Manila Times
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - The Manila Times
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months - The Manila Times
ZenaTech Closes Acquisition of Vara 3D, a Utah-Based Surveying and Mapping Firm Expanding Drone-as-a-Service to the High-Growth Solar Infrastructure Market - The Manila Times
Getty Realty Corp. To Report Fourth Quarter 2025 Financial Results - The Manila Times
dLocal completes transition to a majority independent Board with appointments of Paco Ybarra and Nelson Mattos - The Manila Times
Cassava Announces Agreement to Settle Securities Class Action Litigation - The Manila Times
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) - The Manila Times
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th - The Manila Times
Genius Group Acquires Lighthouse Studios, to Launch Genius Studios. - The Manila Times
Nuvini Announces Strategic Restructuring of Earnout Liabilities with 36% Reduction - The Manila Times
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors - The Manila Times
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6 - The Manila Times
Safe Harbor Expands Consulting and Managed Services Platform Through Talent-Led Strategic Transaction - The Manila Times
Ronald P. Mathison and MATCO Investments Ltd. File Early Warning Report Regarding Calfrac Well Services Ltd. - The Manila Times
Willis Lease Finance Corporation Announces Closing of $392,900,000 in Fixed Rate Notes - The Manila Times
Director/PDMR Shareholding - The Manila Times
Baiya International Group Inc. Announce Reverse Split Record Date - The Manila Times
Aspocomp Group Plc: Notification of management’s transactionTerhi Launis (acquisition) - The Manila Times
Vaccinex, Inc. Announces $60 million Agreement to Finance - GlobeNewswire
Vaccinex, Inc. Enters into a $60 Million Revenue Sharing Agreement with Pepinemab Development Venture, LP - MarketScreener
Analyzing Whitehawk Therapeutics (NASDAQ:WHWK) & Vaccinex (NASDAQ:VCNX) - Defense World
NeurAxis, Inc. (NRXS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
AIM ImmunoTech Inc. (AIMI) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Revenue per share of Vaccinex, Inc. – OTC:VCNX - TradingView
Vaccinex (NASDAQ:VCNX) Trading 4.2% Higher – Time to Buy? - Defense World
Vaccinex (NASDAQ:VCNX) Stock Price Down 5.7% – Time to Sell? - Defense World
Contrasting Vaccinex (NASDAQ:VCNX) & Palatin Technologies (PINK:PTNT) - Defense World
NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight - PR Newswire UK
What sets apart Novavax option from other COVID-19 vaccines - American Medical Association
Vaccinex, Inc. (NASDAQ:VCNX) Sees Significant Growth in Short Interest - Defense World
GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire
Senators from both parties grilled RFK Jr. on vaccines and more - NPR
Vaccine Development - Gates Foundation
TR | OpenAI4o Maintains Vaccinex(VCNX.US) With Hold Rating, Cuts Target Price to $0.5 - 富途牛牛
Head to Head Survey: Aerovate Therapeutics (NASDAQ:AVTE) vs. Vaccinex (NASDAQ:VCNX) - Defense World
Vaccinex (NASDAQ:VCNX) Trading 26.3% Higher – Here’s Why - Defense World
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ - GlobeNewswire
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - The Malaysian Reserve
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Huntington's Disease Market To Expand Significantly By 2034, States Delveinsight Report Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Menafn
Highest-Paid CEOs - AFL-CIO
Cannabinoid Agonist Clinical Trial Pipeline Appears Robust - GlobeNewswire
Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire
Vaccinex (NASDAQ:VCNX) Shares Down 2.7% – Time to Sell? - Defense World
Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
Vaccinex to Report Promising New Clinical Results of - GlobeNewswire
Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire
0.80%
4.56%
자본화:
|
볼륨(24시간):